Please try another search
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Jung-Jin Seo | 67 | 2002 | Inside Co-Chairman of the Board |
Byoung Hoon Jeon | 67 | 2014 | Independent Outside Director |
Hyong-Gi Kim | 59 | 2014 | CEO & Internal Director |
Woo-Sung Kee | 63 | 2014 | CEO & Internal Director |
Jong Suk Lee | 72 | 2014 | Independent Outside Director |
Jin-seok Seo | - | 2021 | Co-CEO & Inside Co-Chairman of the Board |
Byung-oh Kwon | - | - | Director |
Young-hyeh Ko | - | 2022 | Independent Director |
Keun-young Kim | - | 2022 | Independent Director |
Dae-hyun Yoo | - | 2022 | Independent Director |
Jae-sik Lee | - | 2022 | Independent Director |
Soon-Woo Lee | 74 | 2022 | Independent Director |
Wonkyung Choi | - | 2023 | Independent Director |
Jongmoon Choi | - | 2023 | Independent Director |
Joong Jae Lee | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review